" class="no-js "lang="en-US"> Otsuka Pharmaceutical Development & Commercialization - Medtech Alert
Friday, September 12, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Otsuka Pharmaceutical Development & Commercialization | Pharmtech Focus

Otsuka Pharmaceutical Development & Commercialization

About Otsuka Pharmaceutical Development & Commercialization

Otsuka Pharmaceutical Development & Commercialization

We defy limitation, so that others can too.
Otsuka is a healthcare company driven by our purpose and defined by our beliefs.

There are two Otsuka pharmaceutical industry companies in the U.S.:

Otsuka America Pharmaceutical, Inc. (OAPI) successfully commercializes Otsuka-discovered and in-licensed products in North America.

Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) clinically develops and registers innovative healthcare products on a global basis.

Related Story

Diseases

 Otsuka and Lundbeck Announce FDA Approval of Supplemental New Drug Application for REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer’s Disease | MTA

Otsuka and Lundbeck Announce FDA Approval of Supplemental New Drug Application for REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer’s Disease

May 11 2023

Otsuka Pharmaceutical and Lundbeck announce the U.S. Food and Drug Administration (FDA) has approved the supplemental New […]

Clinical Trials

 Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder | MTA

Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder

April 26 2023

Sunovion Pharmaceuticals and Otsuka Pharmaceutical Development & Commercialization today announced that the first patient has […]

Clinical Trials

 PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials | Pharmtech Focus

PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials

August 18 2022

The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the execution of […]

Artificial Intelligence

 Otsuka Signs Three-Year Collaboration with Holmusk to Enhance Digital Health and Data Analytics for Global Behavioral Health Programs | Pharmtech Focus

Otsuka Signs Three-Year Collaboration with Holmusk to Enhance Digital Health and Data Analytics for Global Behavioral Health Programs

July 7 2021

Otsuka Pharmaceutical Development & Commercialization, Inc. (“Otsuka”), announces today that it has entered a three-year […]